Replies to post #253094 on Biotech Values

[dewophile]

among the programs cut is the infant RSV vaccine

[DewDiligence]

MRNA—(-20%)—reduces 2025 revenue guidance:

https://www.accesswire.com/967378/moderna-provides-business-and-pipeline-updates-at-43rd-annual-jp-morgan-healthcare-conference

The new 2025 revenue guidance is $1.5-2.5B, down from the $2.5-3.5B 2025 revenue guidance issued in Sep 2024 (#msg-175073473).